United Therapeutics Corp expected to post earnings of $5.65 a share - Earnings Preview

United Therapeutics

29/04/2024 16:30

* United Therapeutics Corp  UTHR.OQ   UTHR.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 1
for the period ending March 31 2024
    * The Silver Spring Maryland-based  company is expected to
report
a 23.1% increase in revenue to $623.966 million from $506.9
million a year ago, according to the mean estimate from 12
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for United Therapeutics Corp
is
for earnings of $5.65 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.3%
in the last three months. ​
    * Wall Street's median 12-month price target for United
Therapeutics Corp is $304.29​, above​ its last closing price
of $233.85. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  4.09        4.19       4.36      Beat    4.2
 Sep. 30 2023              5.04       5.38      Beat    6.7
 Jun. 30 2023              4.51       5.24      Beat    16.3​
 Mar. 31 2023  4.41        4.52       4.86      Beat    7.4
 ​​Jan.        4.54        4.51       2.67      Missed  -40.8
 1 0001                                                 
 Sep. 30 2022  4.00        3.89       4.91      Beat    26.1​
 Jun. 30 2022  4.02        4.13       2.41      Missed  -41.7
 Mar. 31 2022  3.30        3.35       5.03      Beat    50.4
 This summary was machine generated April 29 at 15:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)